Abstract
The use of tumor necrosis factor antagonists (anti-TNF) has become a usual practice to treat various inflammatory diseases. Although indicated for the treatment of psoriasis, anti-TNF may paradoxically trigger a psoriasiform condition. We present a case of a female patient who, during the use of etanercept for rheumatoid arthritis, developed psoriasis. After histopathological confirmation and consultation, the dermatologist concluded that psoriasis was a paradoxical effect of anti-TNF inhibitors. Anti-TNF inhibitor is replaced with other biological drugtocilizumab. After the change of the drug, psoriasis eruptions were completely resolved. The paradoxical form of psoriasis after the use of anti-TNF inhibitor requires a change of the drug with other mechanism of action
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have